S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
NASDAQ:SNNA

Sienna Biopharmaceuticals (SNNA) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$0.11
$0.17
50-Day Range
$0.14
$0.14
52-Week Range
$0.06
$3.80
Volume
13.32 million shs
Average Volume
1.87 million shs
Market Capitalization
$4.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
SNNA stock logo

About Sienna Biopharmaceuticals Stock (NASDAQ:SNNA)

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that focuses on the discovery, clinical development, and commercialization of aesthetics and medical dermatology. Its products include Topical by Design platform for patients with inflammatory skin diseases and other dermatologic and aesthetic conditions through SNA-120, SNA-125, and SNA-001. The company was founded by Todd Harris and Frederick C. Beddingfield III on July 27, 2010 and is headquartered in Westlake Village, CA.

SNNA Stock News Headlines

[Urgent!] Generational Wealth Gameplan
A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.
[Urgent!] Generational Wealth Gameplan
A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.
See More Headlines
Receive SNNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sienna Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/14/2019
Today
4/17/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SNNA
Fax
N/A
Employees
39
Year Founded
N/A

Profitability

Net Income
$-73,470,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.27 per share

Miscellaneous

Free Float
N/A
Market Cap
$4.20 million
Optionable
Not Optionable
Beta
2.67
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Frederick C. Beddingfield
    President, Chief Executive Officer & Director
  • Majed Kheir
    Vice President-Operations
  • Paul F. Lizzul
    Chief Medical Officer
  • Silvio Traversa
    Chief Scientific Officer
  • Todd J. Harris
    Director & Head-Corporate Development

SNNA Stock Analysis - Frequently Asked Questions

How were Sienna Biopharmaceuticals' earnings last quarter?

Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) announced its quarterly earnings data on Thursday, March, 14th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.83) by $0.10.

What other stocks do shareholders of Sienna Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sienna Biopharmaceuticals investors own include SCYNEXIS (SCYX), Allena Pharmaceuticals (ALNA), Spectrum Pharmaceuticals (SPPI), Selecta Biosciences (SELB), Viking Therapeutics (VKTX), Novavax (NVAX), Synergy Pharmaceuticals (SGYP), Zealand Pharma A/S (ZEAL) and Bausch Health Companies (BHC).

When did Sienna Biopharmaceuticals IPO?

Sienna Biopharmaceuticals (SNNA) raised $64 million in an IPO on Thursday, July 27th 2017. The company issued 4,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and BMO Capital Markets acted as the underwriters for the IPO.

This page (NASDAQ:SNNA) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners